HLS Therapeutics Inc (HLS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, HLS Therapeutics Inc (HLS) has a cash flow conversion efficiency ratio of 0.105x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$6.44 Million ≈ $4.66 Million USD) by net assets (CA$61.56 Million ≈ $44.53 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See HLS defensive interval ratio to measure how many days the company can operate on defensive assets alone.
HLS Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how HLS Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
HLS Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HLS Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Champion Building Materials Co Ltd
TW:1806
|
0.048x |
|
Kura Sushi Asia Co Ltd
TWO:2754
|
0.118x |
|
Prevas AB
ST:PREV-B
|
0.058x |
|
LOT VACUUM Co. Ltd
KQ:083310
|
-0.005x |
|
Studentbostader I Sverige AB
ST:STUDBO
|
0.002x |
|
Raba Jarmuipari Holding Nyrt
BUD:RABA
|
0.085x |
|
Topower Co Ltd
TWO:3226
|
0.017x |
|
Axis Corporation
TWO:6292
|
0.190x |
Annual Cash Flow Conversion Efficiency for HLS Therapeutics Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of HLS Therapeutics Inc from 1996 to 2025. For the full company profile with market capitalisation and key ratios, see how much is HLS Therapeutics Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$61.56 Million ≈ $44.53 Million |
CA$16.02 Million ≈ $11.59 Million |
0.260x | +131.95% |
| 2024-12-31 | CA$71.34 Million ≈ $51.61 Million |
CA$8.00 Million ≈ $5.79 Million |
0.112x | -30.59% |
| 2023-12-31 | CA$97.70 Million ≈ $70.67 Million |
CA$15.79 Million ≈ $11.42 Million |
0.162x | +19.54% |
| 2022-12-31 | CA$125.32 Million ≈ $90.65 Million |
CA$16.94 Million ≈ $12.26 Million |
0.135x | +32.27% |
| 2021-12-31 | CA$160.74 Million ≈ $116.27 Million |
CA$16.43 Million ≈ $11.88 Million |
0.102x | +85.14% |
| 2020-12-31 | CA$169.25 Million ≈ $122.43 Million |
CA$9.34 Million ≈ $6.76 Million |
0.055x | -62.75% |
| 2019-12-31 | CA$178.20 Million ≈ $128.91 Million |
CA$26.41 Million ≈ $19.10 Million |
0.148x | -28.28% |
| 2018-12-31 | CA$158.49 Million ≈ $114.65 Million |
CA$32.75 Million ≈ $23.69 Million |
0.207x | +37.20% |
| 2017-12-31 | CA$180.38 Million ≈ $130.49 Million |
CA$27.17 Million ≈ $19.65 Million |
0.151x | +3562.31% |
| 2016-12-31 | CA$24.97 Million ≈ $18.06 Million |
CA$-108.62K ≈ $-78.58K |
-0.004x | +96.16% |
| 2015-12-31 | CA$26.03 Million ≈ $18.83 Million |
CA$-2.94 Million ≈ $-2.13 Million |
-0.113x | -129.05% |
| 2014-12-31 | CA$46.75 Million ≈ $33.82 Million |
CA$18.21 Million ≈ $13.17 Million |
0.389x | -12.46% |
| 2013-12-31 | CA$40.53 Million ≈ $29.32 Million |
CA$18.03 Million ≈ $13.04 Million |
0.445x | -14.10% |
| 2012-12-31 | CA$40.99 Million ≈ $29.65 Million |
CA$21.23 Million ≈ $15.36 Million |
0.518x | -5.88% |
| 2011-12-31 | CA$32.56 Million ≈ $23.55 Million |
CA$17.92 Million ≈ $12.96 Million |
0.550x | -27.03% |
| 2010-12-31 | CA$33.23 Million ≈ $24.04 Million |
CA$25.06 Million ≈ $18.13 Million |
0.754x | +408.59% |
| 2009-12-31 | CA$35.90 Million ≈ $25.97 Million |
CA$5.32 Million ≈ $3.85 Million |
0.148x | -24.36% |
| 2008-12-31 | CA$28.33 Million ≈ $20.50 Million |
CA$5.55 Million ≈ $4.02 Million |
0.196x | -55.32% |
| 2007-12-31 | CA$50.09 Million ≈ $36.24 Million |
CA$21.98 Million ≈ $15.90 Million |
0.439x | +1816.11% |
| 2006-12-31 | CA$30.72 Million ≈ $22.23 Million |
CA$703.50K ≈ $508.90K |
0.023x | -94.50% |
| 2005-12-31 | CA$30.02 Million ≈ $21.72 Million |
CA$12.50 Million ≈ $9.04 Million |
0.416x | +208.31% |
| 2004-12-31 | CA$18.42 Million ≈ $13.33 Million |
CA$2.49 Million ≈ $1.80 Million |
0.135x | -26.74% |
| 2003-12-31 | CA$26.67 Million ≈ $19.30 Million |
CA$4.92 Million ≈ $3.56 Million |
0.184x | -35.68% |
| 2002-12-31 | CA$24.47 Million ≈ $17.70 Million |
CA$7.01 Million ≈ $5.07 Million |
0.287x | +135.36% |
| 2001-12-31 | CA$24.45 Million ≈ $17.69 Million |
CA$2.98 Million ≈ $2.15 Million |
0.122x | -76.93% |
| 2000-12-31 | CA$12.48 Million ≈ $9.03 Million |
CA$6.59 Million ≈ $4.77 Million |
0.528x | +64.79% |
| 1999-12-31 | CA$14.22 Million ≈ $10.29 Million |
CA$4.56 Million ≈ $3.30 Million |
0.320x | +5033.98% |
| 1998-12-31 | CA$10.01 Million ≈ $7.24 Million |
CA$-64.99K ≈ $-47.01K |
-0.006x | -101.99% |
| 1997-12-31 | CA$16.91 Million ≈ $12.23 Million |
CA$5.52 Million ≈ $3.99 Million |
0.326x | -70.75% |
| 1996-12-31 | CA$8.31 Million ≈ $6.01 Million |
CA$9.27 Million ≈ $6.71 Million |
1.116x | -- |
About HLS Therapeutics Inc
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances … Read more